window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : July 30, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

phase 3 trial

  • Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Opinion & Events,Therapeutic Areas

    Cook MyoSite and Veristat progress Phase 3 trial of cell therapy for women with chronic incontinence

    Cook MyoSite and Veristat have reached a key enrolment milestone [...]

    May 5, 2026
  • Uncategorised

    Pharvaris eyes 2026 filing as Phase 3 HAE trial timeline shifts

    Pharvaris has adjusted its guidance for topline results from its [...]

    July 10, 2025
  • Advanced Therapies,Clinical & Regulatory,Drug Discovery & Development

    Novadip’s autologous cell therapy NVD003 receives RMAT designation for rare pediatric bone disorder

    FDA recognises regenerative approach for congenital pseudarthrosis of the tibia [...]

    May 5, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Therapeutic Areas

    Enterome secures $19M to progress OncoMimics immunotherapy in indolent non-Hodgkin lymphoma

    Funding to advance EO2463 through Phase 1/2 and prepare for [...]

    May 5, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Opinion & Events

    NICE backs mirikizumab for treatment-resistant Crohn’s disease

    The National Institute for Health and Care Excellence (NICE) has [...]

    May 5, 2026
Previous23

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • ViiV Healthcare HIV regimen Dovato non-inferior to Biktarvy in Phase 3b study
    Categories: Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development
  • Seegene data finds STI pathogens in 82% of HPV-positive test results
    Categories: Clinical & Regulatory, Medical devices, Pharmaceuticals and therapeutics, Research & Development
  • AI-driven antibody discovery could create $7bn market for life science tools
    Categories: Digital & Data, Drug Delivery & Formulation, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top